PT3103802T - Novo composto de pirrolopirimidina ou seu sal, composição farmacêutica que o contém, especialmente agente para prevenção e/ou tratamento de tumores etc. com base no efeito inibidor de nae - Google Patents

Novo composto de pirrolopirimidina ou seu sal, composição farmacêutica que o contém, especialmente agente para prevenção e/ou tratamento de tumores etc. com base no efeito inibidor de nae Download PDF

Info

Publication number
PT3103802T
PT3103802T PT158113415T PT15811341T PT3103802T PT 3103802 T PT3103802 T PT 3103802T PT 158113415 T PT158113415 T PT 158113415T PT 15811341 T PT15811341 T PT 15811341T PT 3103802 T PT3103802 T PT 3103802T
Authority
PT
Portugal
Prior art keywords
group
ethynyl
amino
methyl
pyrrolo
Prior art date
Application number
PT158113415T
Other languages
English (en)
Portuguese (pt)
Inventor
Mizutani Takashi
Yoshimura Chihoko
Kondo Hitomi
Kitade Makoto
Ohkubo Shuichi
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Publication of PT3103802T publication Critical patent/PT3103802T/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
PT158113415T 2014-06-24 2015-06-24 Novo composto de pirrolopirimidina ou seu sal, composição farmacêutica que o contém, especialmente agente para prevenção e/ou tratamento de tumores etc. com base no efeito inibidor de nae PT3103802T (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2014129740 2014-06-24
JP2015024785 2015-02-10

Publications (1)

Publication Number Publication Date
PT3103802T true PT3103802T (pt) 2017-12-11

Family

ID=54938214

Family Applications (1)

Application Number Title Priority Date Filing Date
PT158113415T PT3103802T (pt) 2014-06-24 2015-06-24 Novo composto de pirrolopirimidina ou seu sal, composição farmacêutica que o contém, especialmente agente para prevenção e/ou tratamento de tumores etc. com base no efeito inibidor de nae

Country Status (21)

Country Link
US (2) US9963456B2 (enExample)
EP (1) EP3103802B1 (enExample)
JP (1) JP6192741B2 (enExample)
KR (1) KR101947289B1 (enExample)
CN (1) CN106661031B (enExample)
AU (1) AU2015281155B9 (enExample)
BR (1) BR112016025835B1 (enExample)
CA (1) CA2946833C (enExample)
DK (1) DK3103802T3 (enExample)
ES (1) ES2656772T3 (enExample)
HU (1) HUE037266T2 (enExample)
MX (1) MX2016015015A (enExample)
MY (1) MY183327A (enExample)
NO (1) NO3103802T3 (enExample)
PH (1) PH12016502130A1 (enExample)
PL (1) PL3103802T3 (enExample)
PT (1) PT3103802T (enExample)
RU (1) RU2658008C2 (enExample)
SG (1) SG11201608441YA (enExample)
TW (1) TWI605048B (enExample)
WO (1) WO2015199136A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI623316B (zh) * 2015-12-22 2018-05-11 Taiho Pharmaceutical Co Ltd Antitumor effect enhancer derived from pyrrolopyrimidine compound
WO2018085818A1 (en) * 2016-11-07 2018-05-11 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
WO2018085833A2 (en) * 2016-11-07 2018-05-11 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyl transferase 5 (prmt5)
US10865208B2 (en) 2016-11-11 2020-12-15 Millennium Pharmaceuticals, Inc. ATG7 inhibitors and the uses thereof
JP7125714B2 (ja) * 2016-12-13 2022-08-25 ヤマサ醤油株式会社 抗ウイルス活性を有する2’-デオキシ-7-デアザプリンヌクレオシド誘導体
EP3740491A1 (en) * 2018-01-18 2020-11-25 Array Biopharma, Inc. Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
CN108822145B (zh) * 2018-06-11 2020-10-23 广东工业大学 一种磺酰胺类化合物及其制备方法和应用
CN108640945B (zh) * 2018-06-11 2020-10-23 广东工业大学 一种酰胺类化合物及其制备方法与应用
WO2020014541A2 (en) * 2018-07-13 2020-01-16 Il-2Rx, Inc. Compounds, compositions, methods, and uses for treating cancer and immunological disorders

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1848718B1 (en) * 2005-02-04 2012-08-01 Millennium Pharmaceuticals, Inc. Inhibitors of e1 activating enzymes
US7989430B2 (en) * 2005-12-06 2011-08-02 Regents Of The University Of Minnesota Antibacterial agents
MY171289A (en) 2006-02-02 2019-10-07 Millennium Pharm Inc Inhibitors of e1 activating enzymes
WO2012061551A1 (en) * 2010-11-05 2012-05-10 Millennium Pharmaceuticals, Inc. Administration of nedd8-activating enzyme inhibitor
JP2014501772A (ja) 2011-01-07 2014-01-23 レオ ファーマ アクティーゼルスカブ タンパク質チロシンキナーゼ阻害薬としての新規スルファミドピペラジン誘導体およびその医薬用途
WO2013016906A1 (zh) * 2011-07-29 2013-02-07 深圳光启高等理工研究院 人工复合材料和人工复合材料天线
PT2657233E (pt) * 2012-01-19 2014-10-24 Taiho Pharmaceutical Co Ltd Composto de alcinil-benzeno substituído nas posições 3 e 5 e um seu sal

Also Published As

Publication number Publication date
CA2946833C (en) 2019-03-05
SG11201608441YA (en) 2016-11-29
TWI605048B (zh) 2017-11-11
AU2015281155B2 (en) 2017-07-13
KR20170016510A (ko) 2017-02-13
AU2015281155A1 (en) 2016-11-03
RU2658008C2 (ru) 2018-06-19
BR112016025835A2 (enExample) 2017-08-15
CN106661031A (zh) 2017-05-10
CA2946833A1 (en) 2015-12-30
PL3103802T3 (pl) 2018-02-28
NO3103802T3 (enExample) 2018-04-07
US20170066772A1 (en) 2017-03-09
RU2016149319A3 (enExample) 2018-06-18
TW201625629A (zh) 2016-07-16
EP3103802A4 (en) 2017-03-08
PH12016502130B1 (en) 2016-12-19
CN106661031B (zh) 2019-07-23
JP6192741B2 (ja) 2017-09-06
MY183327A (en) 2021-02-18
AU2015281155B9 (en) 2017-11-16
BR112016025835B1 (pt) 2022-09-20
DK3103802T3 (en) 2017-12-11
US10174040B2 (en) 2019-01-08
US9963456B2 (en) 2018-05-08
WO2015199136A1 (ja) 2015-12-30
ES2656772T3 (es) 2018-02-28
HUE037266T2 (hu) 2018-08-28
JPWO2015199136A1 (ja) 2017-04-27
PH12016502130A1 (en) 2016-12-19
RU2016149319A (ru) 2018-06-18
US20180162864A1 (en) 2018-06-14
KR101947289B1 (ko) 2019-02-12
EP3103802B1 (en) 2017-11-08
MX2016015015A (es) 2017-02-27
EP3103802A1 (en) 2016-12-14

Similar Documents

Publication Publication Date Title
AU2016379290B2 (en) Antitumor effect potentiator comprising pyrrolopyrimidine compound
DK3103802T3 (en) NEW PYRROLOPYRIMIDINE COMPOUND OR SALT THEREOF, PHARMACEUTICAL COMPOSITION CONTAINING SAME, SPECIFICALLY MEDICINE TO PREVENT AND / OR TREAT TUMORS ETC. BASED ON NAE-INHIBITIVE EFFECTS
JP5832524B2 (ja) ピリドン及びアザピリドン化合物、並びにそれらの使用方法
RU2666349C2 (ru) Новое конденсированное пиримидиновое соединение или его соль
KR20240127910A (ko) Sos1 억제제 및 항암제를 포함하는 암 치료용 약학 조성물
HK1236948B (zh) 毗咯并嘧啶化合物或其盐、含有其的药物组合物及应用
HK1236948A1 (en) Pyrrolopyrimidine compound or salt thereof, pharmaceutical composition containing same, and applications
WO2025043225A2 (en) Degraders of cyclin-dependent kinase 2
HK1243417B (zh) 吡啶酮和氮杂吡啶酮化合物及使用方法